Sequenta's MRD Detection Test Predicts Post-Transplant Relapse and Survival in ALL

Sequenta's ClonoSIGHT that uses next generation sequencing to detect minimal residual disease, provides prognosis on relapse and survival of post-transplant ALL patients.

Sequenta, Inc. and collaborators have published results demonstrating that the company’s next-generation sequencing-based minimal residual disease (MRD) quantification technology, available clinically as the ClonoSIGHT™ test, provides important prognostic information about adult patients with acute lymphoblastic leukemia (ALL) who receive donor stem cell transplants. Analysis of post-transplant blood samples with Sequenta’s method predicted both relapse and survival and detected evidence of disease a median of three months prior to clinical relapse.

“Minimal residual disease testing has become a standard of care in the management of pediatric ALL, but routine assessment of MRD in adult patients remains uncommon due to the varied diagnostic capabilities of hospitals across the country and the usual requirement for bone marrow samples,” said Aaron Logan, M.D., Ph.D., Assistant Professor, UCSF School of Medicine, lead author of the study. “The ClonoSIGHT test has the advantages of being standardized and sufficiently sensitive to detect MRD in blood samples, making it a powerful tool for assessing responses to treatment and for studying methods to improve patient outcomes by intervening on progressive MRD instead of awaiting overt relapse.”

Read the press release here:

Source: Yahoo! finance

Related Videos
View All
Related Content
© 2023 MJH Life Sciences
All rights reserved.